<u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishesa minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided:section/paragraph)	n/a
For commercial reagents, provide supplier	Methods	
name, catalogue number and RRID, if available.	Western blotting	
, ,		

Cell materials	Yes (indicate where provided:section/paragraph)	n/a
Cell lines: Provide species information, strain. Provide accession number in repository OR supplier name, catalog number, clone number, OR RRID	Methods Cell culture, transfection and reagent	
Primary cultures: Provide species, strain, sex of		n/a
origin, genetic modification status.		

Experimental animals	Yes (indicate where provided:section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age,		n/a
genetic modification status. Provide accession		
number in repository OR supplier name, catalog		
number, clone number, OR RRID		
Animal observed in or captured from the		n/a
field: Provide species, sex and age where		
possible		
Model organisms: Provide Accession number		n/a
in repository (where relevant) OR RRID		

Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)		n/a
Microbes:provide species and strain, unique accession number if available, and source		n/a

Human research participants	Yes (indicate where provided:section/paragraph)	n/a
Identify authority granting ethics approval (IRB or	#Methods	
equivalent committee(s), provide reference number	##Tissue samples	
for approval.		
Provide statement confirming informed consent	#Methods	
obtained from study participants.	##Tissue samples	
Report on age and sex for all study participants.	#Methods	
	##Tissue samples	

Design

Studyprotocol	Yes (indicate where provided:section/paragraph)	n/a
For clinical trials, provide the trial registration		n/
number OR cite DOI in manuscript.		а

Laboratoryprotocol	Yes (indicate where provided:section/paragraph)	n/a
Provide DOI or other citation details if detailed step-		n/
by-step protocols are available.		а

Experimental study design (statistics details)	Yes (indicate where provided:section/paragraph)	n/a
State whether and how the following have been		n/
done, or if they were not carried out.		а
Sample size determination		n/
Randomisation		n/
Blinding		n/
Inclusion/exclusion criteria		n/

Sample definition and in-laboratory replication	Yes (indicate where provided:section/paragraph)	n/a
State number of times the experiment was		n/
replicated in laboratory		а
Define whether data describe technical or biological		n/
replicates		а

Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of	#Methods	
authority granting ethics approval (IRB or equivalent	##Tissue samples	
committee(s), provide reference number for		
approval.		
Studies involving experimental animals: State details		n/a
of authority granting ethics approval (IRB or		
equivalent committee(s), provide reference number		
for approval.		
Studies involving specimen and field samples: State if	#Methods	
relevant permits obtained, provide details of	##Tissue samples	
authority approving study; if none were required,		
explain why.		

Dual Use Research of Concern (DURC)	Yes (indicate where provided:section/paragraph)	n/a
If study is subject to dual use research ofconcern,		n/
statethe authority granting approval and reference		а
number for the regulatory approval		

<u>Analysis</u>

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is		n/
excluded, and whether the criteria for exclusion were		а
determined and specified in advance.		

Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describestatistical tests used and justify choice of	Statistical analysis	
tests.		

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available,	Footnote	
including protocols for access or restriction on	Data Sharing Statement:	
access.		
If data are publicly available, provide accession	Footnote	
number in repository or DOI or URL.	Data Sharing Statement:	
If publicly available data are reused, provide	Footnote	
accession number in repository or DOI or URL, where	Data Sharing Statement:	
possible.		

Code Availability	Yes (indicate where provided:section/paragraph)	n/a
For all newly generated code and software essential		n/
for replicating the main findings of the study:		а
State whether the code or software is available.		n/
If code is publicly available, provide accession		n/
number in repository, or DOI or URL.		а

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of		
discipline-specific guidelines, established and		
endorsed through community initiatives. Journals		
have their own policy about requiring specific		
guidelines and recommendations to complement		
MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI,	ICMJE guidelines were followed, as the journal follows	
ARRIVE) have been followed, and whether a checklist	ICMJE recommendations for publication.	
(eg., CONSORT, PRISMA, ARRIVE) is provided with		
the manuscript.		

Article information: https://dx.doi.org/10.21037/atm-21-6556